Algert Global LLC reduced its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) by 8.6% in ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) had its price target trimmed by Citigroup from $27.00 to $26.00 in a ...

Goldman has recently initiated Arrowhead Pharmaceuticals Inc (ARWR) stock to Neutral rating, as announced on June 5, 2024, according to Finviz. Earlier, on December 4, 2023, BofA Securities had ...

Q4 2024 Earnings Call Transcript November 26, 2024 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Arrowhead Pharmaceuticals, Inc. (ARWR) has disclosed a new risk, in the Sales & Marketing category.Don't Miss our Black Friday ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

After the market close on Tuesday, Iris reported first-quarter Bitcoin BTC/USD mining revenue of $49.6 million. The company ...

Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...

Arrowhead Pharmaceuticals, Inc. ( (ARWR) ) has released its Q4 earnings. Here is a breakdown of the information Arrowhead Pharmaceuticals, Inc.